Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib plus Iparomlimab and Tuvorralimab in Advanced/Recurrent Metastatic Cervical Cancer
ChiCTR2500111354Phase 2Not yet recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of famitinib, iparomlimab and ambuzutinib in Cervical Cancer (CC) (2 arms), sponsored by Xinhua Hospital. Primary endpoints: Treatment-related adverse events (TRAEs), Objective response rate (ORR) and 1 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
famitinibiparomlimabambuzutinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500111354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111354.